Data as of Nov 21
| +0.19 / +1.68%|
The 9 analysts offering 12-month price forecasts for Momenta Pharmaceuticals Inc have a median target of 15.00, with a high estimate of 18.00 and a low estimate of 12.50. The median estimate represents a +30.32% increase from the last price of 11.51.
The current consensus among 9 polled investment analysts is to Buy stock in Momenta Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.